148 related articles for article (PubMed ID: 25561284)
1. Ginsenoside Rh2 Targets EGFR by Up-Regulation of miR-491 to Enhance Anti-tumor Activity in Hepatitis B Virus-Related Hepatocellular Carcinoma.
Chen W; Qiu Y
Cell Biochem Biophys; 2015 Jun; 72(2):325-31. PubMed ID: 25561284
[TBL] [Abstract][Full Text] [Related]
2. EGFR signaling-dependent inhibition of glioblastoma growth by ginsenoside Rh2.
Li S; Gao Y; Ma W; Guo W; Zhou G; Cheng T; Liu Y
Tumour Biol; 2014 Jun; 35(6):5593-8. PubMed ID: 24557544
[TBL] [Abstract][Full Text] [Related]
3. Antitumoral Activity of (20R)- and (20S)-Ginsenoside Rh2 on Transplanted Hepatocellular Carcinoma in Mice.
Lv Q; Rong N; Liu LJ; Xu XL; Liu JT; Jin FX; Wang CM
Planta Med; 2016 May; 82(8):705-11. PubMed ID: 27163230
[TBL] [Abstract][Full Text] [Related]
4. Microarray analysis of altered long non-coding RNA expression profile in liver cancer cells treated by ginsenoside Rh2.
Chen WW; Huang YF; Hu ZB; Liu YM; Xiao HX; Liu DB; Zhuang YZ
J Asian Nat Prod Res; 2019 Aug; 21(8):742-753. PubMed ID: 30394104
[TBL] [Abstract][Full Text] [Related]
5. Upregulated in Hepatitis B virus-associated hepatocellular carcinoma cells, miR-331-3p promotes proliferation of hepatocellular carcinoma cells by targeting ING5.
Cao Y; Chen J; Wang D; Peng H; Tan X; Xiong D; Huang A; Tang H
Oncotarget; 2015 Nov; 6(35):38093-106. PubMed ID: 26497554
[TBL] [Abstract][Full Text] [Related]
6. 20(S)-Ginsenoside Rh2 suppresses proliferation and migration of hepatocellular carcinoma cells by targeting EZH2 to regulate CDKN2A-2B gene cluster transcription.
Li Q; Li B; Dong C; Wang Y; Li Q
Eur J Pharmacol; 2017 Nov; 815():173-180. PubMed ID: 28928088
[TBL] [Abstract][Full Text] [Related]
7. 20(S)-Ginsenoside Rh2 inhibits hepatocellular carcinoma by suppressing angiogenesis and the GPC3-mediated Wnt/β‑catenin signaling pathway.
Xu L; Li J; Hou N; Han F; Sun X; Li Q
Acta Biochim Biophys Sin (Shanghai); 2024 Apr; 56(5):688-696. PubMed ID: 38584523
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of microRNA-15b by hepatitis B virus X enhances hepatocellular carcinoma proliferation via fucosyltransferase 2-induced Globo H expression.
Wu CS; Yen CJ; Chou RH; Chen JN; Huang WC; Wu CY; Yu YL
Int J Cancer; 2014 Apr; 134(7):1638-47. PubMed ID: 24122375
[TBL] [Abstract][Full Text] [Related]
9. The identification of molecular target of (20S) ginsenoside Rh2 for its anti-cancer activity.
Wang YS; Lin Y; Li H; Li Y; Song Z; Jin YH
Sci Rep; 2017 Sep; 7(1):12408. PubMed ID: 28963461
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects of ginsenoside Rg3 on human hepatocellular carcinoma cells.
Zhang C; Liu L; Yu Y; Chen B; Tang C; Li X
Mol Med Rep; 2012 May; 5(5):1295-8. PubMed ID: 22366885
[TBL] [Abstract][Full Text] [Related]
11. Mannose-mediated inhibitory effects of PA-MSHA on invasion and metastasis of hepatocellular carcinoma via EGFR/Akt/IκBβ/NF-κB pathway.
Li T; Dong ZR; Guo ZY; Wang CH; Zhi XT; Zhou JW; Li DK; Chen ZT; Chen ZQ; Hu SY
Liver Int; 2015 Apr; 35(4):1416-29. PubMed ID: 25066210
[TBL] [Abstract][Full Text] [Related]
12. Ginsenoside Rg3 Decreases NHE1 Expression via Inhibiting EGF-EGFR-ERK1/2-HIF-1
Li X; Tsauo J; Geng C; Zhao H; Lei X; Li X
Am J Chin Med; 2018; 46(8):1915-1931. PubMed ID: 30525897
[TBL] [Abstract][Full Text] [Related]
13. Functional analysis of miR-181a and Fas involved in hepatitis B virus-related hepatocellular carcinoma pathogenesis.
Zou C; Chen J; Chen K; Wang S; Cao Y; Zhang J; Sheng Y; Huang A; Tang H
Exp Cell Res; 2015 Feb; 331(2):352-61. PubMed ID: 25449696
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic effect of a multi-targeted imidazolium compound in hepatocellular carcinoma.
Gopalan B; Narayanan K; Ke Z; Lu T; Zhang Y; Zhuo L
Biomaterials; 2014 Aug; 35(26):7479-87. PubMed ID: 24912819
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
[TBL] [Abstract][Full Text] [Related]
17. Ginsenoside 20(S)-Rh2 exerts anti-cancer activity through targeting IL-6-induced JAK2/STAT3 pathway in human colorectal cancer cells.
Han S; Jeong AJ; Yang H; Bin Kang K; Lee H; Yi EH; Kim BH; Cho CH; Chung JW; Sung SH; Ye SK
J Ethnopharmacol; 2016 Dec; 194():83-90. PubMed ID: 27566200
[TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
[TBL] [Abstract][Full Text] [Related]
19. Upregulated miR-182 increases drug resistance in cisplatin-treated HCC cell by regulating TP53INP1.
Qin J; Luo M; Qian H; Chen W
Gene; 2014 Apr; 538(2):342-7. PubMed ID: 24447717
[TBL] [Abstract][Full Text] [Related]
20. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
Xu H; Zhao L; Fang Q; Sun J; Zhang S; Zhan C; Liu S; Zhang Y
PLoS One; 2014; 9(12):e115565. PubMed ID: 25531114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
